Presentation is loading. Please wait.

Presentation is loading. Please wait.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia by Davide Rossi, Lodovico.

Published byHallgeir Bråthen Modified over 5 years ago

Similar presentations

Presentation on theme: "Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia by Davide Rossi, Lodovico."— Presentation transcript:

1 Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia by Davide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R. Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Francesco Forconi, Luca Laurenti, Ilaria Del Giudice, Massimo Gentile, Iolanda Vincelli, Marina Motta, Marta Coscia, Gian Matteo Rigolin, Alessandra Tedeschi, Antonino Neri, Roberto Marasca, Omar Perbellini, Carol Moreno, Giovanni Del Poeta, Massimo Massaia, Pier Luigi Zinzani, Marco Montillo, Antonio Cuneo, Valter Gattei, Robin Foà, and Gianluca Gaidano Blood Volume 126(16): October 15, 2015 ©2015 by American Society of Hematology

2 Estimates of PFS, hazard of progression, OS, and prevalence of second tumors according to the model based on 17p deletion, 11q deletion, and IGHV mutation status. Estimates of PFS, hazard of progression, OS, and prevalence of second tumors according to the model based on 17p deletion, 11q deletion, and IGHV mutation status. High-risk cases harboring 17p deletion independent of co-occurring 11q deletion or unmutated IGHV genes are color-coded in red. Intermediate-risk cases harboring unmutated IGHV genes and/or 11q deletion in the absence of 17p deletion are color-coded in yellow. Low-risk cases harboring mutated IGHV genes in the absence of 11q and 17p deletion are color-coded in blue. (A) PFS. (B) Estimate of the hazard of progression in relation to the time elapsed from FCR treatment start. (C) OS. The black line represents the expected OS in the age, sex, and calendar year of treatment-matched general population. P values according to Log-rank statistics. (D) Prevalence of second tumors among assessable cases of the three risk subgroups. Whiskers represent the 95% confidence interval (CI) of the proportion. P value according to Fisher’s exact test. na, not applicable; nr, not reached. Davide Rossi et al. Blood 2015;126: ©2015 by American Society of Hematology

Download ppt "Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia by Davide Rossi, Lodovico."

Similar presentations

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination by Giulia Benevolo,

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination by Giulia Benevolo,
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.

Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
Geisler C et al. Proc ASH 2011;Abstract 290.

Geisler C et al. Proc ASH 2011;Abstract 290.
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.
Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio.

Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio.
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Rituximab-induced tumor cell agglutination

Rituximab-induced tumor cell agglutination
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European.

High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European.
One giant leap for pediatric AMKL

One giant leap for pediatric AMKL
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia by Agostino Tafuri, Chiara.

MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia by Agostino Tafuri, Chiara.
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.
High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy.

High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy.

Similar presentations

Ads by Google